The 2 most recent market catalysts affecting $GNPX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 18, 2026
Corporate Catalyst
Bullish
Impact 75
Genprex Announces Development And Manufacturing Agreement With Undisclosed U.S. CDMO To Scale Up cGMP Production Of Diabetes Gene Therapy For IND-Enabling Studies, Future Trials
This headline is a significant corporate catalyst for Genprex. Securing a CDMO for cGMP production is a critical de-risking event for any biotech company, especially one developing…
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer
Genprex has announced a strategic partnership with Roche Diagnostics to validate TROP2 and PTEN as biomarkers for patient selection in their Non-Small Cell Lung Cancer (NSCLC) clin…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.